Epithelial TGFβ Engages Growth-factor Signalling to Circumvent Apoptosis and Drive Intestinal Tumourigenesis with Aggressive Features
Overview
Authors
Affiliations
The pro-tumourigenic role of epithelial TGFβ signalling in colorectal cancer (CRC) is controversial. Here, we identify a cohort of born to be bad early-stage (T1) colorectal tumours, with aggressive features and a propensity to disseminate early, that are characterised by high epithelial cell-intrinsic TGFβ signalling. In the presence of concurrent Apc and Kras mutations, activation of epithelial TGFβ signalling rampantly accelerates tumourigenesis and share transcriptional signatures with those of the born to be bad T1 human tumours and predicts recurrence in stage II CRC. Mechanistically, epithelial TGFβ signalling induces a growth-promoting EGFR-signalling module that synergises with mutant APC and KRAS to drive MAPK signalling that re-sensitise tumour cells to MEK and/or EGFR inhibitors. Together, we identify epithelial TGFβ signalling both as a determinant of early dissemination and a potential therapeutic vulnerability of CRC's with born to be bad traits.
Catalano T, Selvaggi F, Cotellese R, Aceto G Cancers (Basel). 2025; 17(5).
PMID: 40075600 PMC: 11899472. DOI: 10.3390/cancers17050752.
Yu L, Yang W, Liang Y Biomedicines. 2025; 12(12.
PMID: 39767678 PMC: 11673925. DOI: 10.3390/biomedicines12122771.
Torang A, Kirov A, Lammers V, Cameron K, Wouters V, Jackstadt R Nat Commun. 2025; 16(1):264.
PMID: 39747069 PMC: 11696116. DOI: 10.1038/s41467-024-55574-3.
Hamada K, Nakanishi Y, Muta Y, Omatsu M, Iwane K, Ikeda M Cell Mol Gastroenterol Hepatol. 2024; 19(3):101435.
PMID: 39631567 PMC: 11786897. DOI: 10.1016/j.jcmgh.2024.101435.
TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance.
Johansen A, Forsythe S, McGrath C, Barker G, Jimenez H, Paluri R Clin Cancer Res. 2024; 30(17):3676-3687.
PMID: 38916900 PMC: 11371528. DOI: 10.1158/1078-0432.CCR-24-0468.